Interleukin-32 circulating levels are associated with hepatic expression and are upregulated in patients with NAFLD; thus, interleukin-32 is a candidate biomarker for the non-invasive evaluation of NAFLD and may be targeted for treatment [119]. Here, IL32 is linked to metabolic dysfunction-associated steatotic liver disease.